340B Program Operations Certificate Practice Exam

The term 'diversion prohibition' in the context of the 340B program specifically addresses the improper use of drugs, particularly the distribution of 340B drug discounts to individuals or entities that do not qualify for the program. This aspect of the program is critical because it ensures that the benefits of 340B pricing are only utilized for eligible patients at qualified healthcare providers, such as safety-net hospitals and community health centers.

By prohibiting diversion, the 340B program aims to prevent entities from transferring or selling discounted drugs to ineligible patients or other parties. This ensures that the intended purpose of the program—providing necessary medications to underserved populations—is upheld and that the savings generated from the 340B drug prices are directed toward improving access to care and health outcomes for those who truly need it.

The other options relate to different aspects of healthcare operations but do not specifically define the focus of diversion prohibition. For example, incorrect billing practices pertain to the financial management and compliance within the program, patient health assessments are related to patient care and eligibility determination, and drug supply chain issues deal with logistics and distribution, rather than the misuse or diversion of discounted medications.